Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause Anaemia? 154 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 154 reports of Anaemia have been filed in association with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (PLUVICTO). This represents 1.4% of all adverse event reports for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN.
154
Reports of Anaemia with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
1.4%
of all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN reports
28
Deaths
62
Hospitalizations
How Dangerous Is Anaemia From LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN?
Of the 154 reports, 28 (18.2%) resulted in death, 62 (40.3%) required hospitalization, and 11 (7.1%) were considered life-threatening.
Is Anaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. However, 154 reports have been filed with the FAERS database.
What Other Side Effects Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause?
General physical health deterioration (4,332)
Ill-defined disorder (3,600)
Death (1,179)
Disease progression (286)
Malignant neoplasm progression (251)
Laboratory test abnormal (233)
Prostatic specific antigen increased (212)
Fatigue (177)
Covid-19 (139)
Platelet count decreased (130)
What Other Drugs Cause Anaemia?
LENALIDOMIDE (5,322)
CARBOPLATIN (5,312)
RIBAVIRIN (5,130)
ASPIRIN (4,568)
CYCLOPHOSPHAMIDE (4,486)
RITUXIMAB (4,399)
DEXAMETHASONE (4,352)
ADALIMUMAB (3,994)
PACLITAXEL (3,949)
METHOTREXATE (3,913)
Which LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Alternatives Have Lower Anaemia Risk?
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTETIUM OXODOTREOTIDE LU-177
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTROPIN ALFA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYMECYCLINE
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYRICA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYSERGIDE